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Introduction
Steroid use has prolonged ambulation in Duchenne
muscular dystrophy (DMD) and combined with advances
in respiratory care overall management has improved such
that cardiac manifestations have become the major cause
of death. Unfortunately, there is no consensus for
DMD-associated cardiac disease management.
Purpose
To assess effects of steroid use alone or in combination
with angiotensin converting enzyme inhibitors (ACEI)
or angiotension receptor blocker (ARB) on cardiac mag-
netic resonance imaging (CMR) derived circumferential
strain (εcc).
Methods
We reviewed our DMD CMR database and medical
records from February 2006 to 2010. The study cohort
was divided into patients receiving steroids alone
(Group A) or steroids plus ACEI or ARB (Group B).
Analysis of covariance was used to assess the effect of
medication on heart rate (HR), left ventricular ejection
fraction (LVEF), mass (LVM), end diastolic volume
(LVEDV) and εcc with age as a continuous covariate.
Results
A total of 206 studies from 136 DMD subjects were
included in the analysis. Group A (114 studies) was younger
than Group B (92 studies)(10±2.4 vs. 12.4±3.2 years,
p < 0.0001). However, HR, LVEF, LVEDV and LVM were
not different between the two groups (Table 1). εcc magni-
tude was significantly lower in Group B (-13.8±1.9 vs -12.8
±2.0, p= 0.0004), but age correction using covariance analy-
sis eliminated this effect (Table 2). After mean follow-up of
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Table 1 DMD Patients characteristics
Parameter Steroid Only (A)
(n=114)
Steroid plus ACEI_ARB
(B) (n=92)
P-value
Age (yrs) 10.0 ± 2.4 12.4 ± 3.2 <0.0001
Heart Rate (bpm) 101 ± 19 104 ± 15 0.2498
LVEDV (mL) 82.5 ± 21.8 86.7 ± 24.8 0.2023
LVM (g) 58.6 ± 19.4 62.1 ± 19.8 0.1031
EF (%) 64.2 ± 6.1 62.8 ± 7.5 0.1414
εcc (%) -13.8 ± 1.9 -12.8 ± 2.0 0.0004
Steroid dose
(gram/kg/day)
0.7 ± 0.29 0.6 ± 0.22 0.4838
ACE-I dose (gram/
kg/day)
N/A 0.16 ± 0.08 N/A
ARB dose (gram/
kg/day)
N/A 0.73 ± 0.29 N/A
Abbreviations: ACE-I = Angiotension Converting Enzyme Inhibitor, ARB =
Angiotension Receptor Block, bpm = beat per minute, Clinic Prior to CMR =
Previous Clinic Visiting Documenting Medication and Dose Prior to Cardiac
Magnetic Resonance Imaging Study, DMD = Duchenne Muscular Dystrophy,
εcc = Circumferential Strain, EF = Ejection Fraction, LVEDV = Left Ventricular
Endiastolic Volume, LVM = Left Ventricular Mass.
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baseline (Table 3).
Conclusions
In a large consecutive database of DMD patients, serial
CMR studies demonstrate that current and standard
treatment strategy at our institution has little effect on
DMD-associated cardiac disease. The failure of current
regimens supports the need for rigorous prospective
clinical trials to identify effective treatment regimens.
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Table 2 Analysis of covariance summary results: Comparisons between steroid only vs. steroid plus ACEI_ARB
(medication) adjusted for age as continuous variable
Medication Age
Response Variable F-statistics P-value F-statistics P-value
Heart Rate (bpm) 1.11 0.2930 0.00 0.9979
LVEDV (mL) 1.33 0.2503 37.01 <0.0001
LVM (g) 2.19 0.1405 64.38 <0.0001
EF (%) 0.03 0.8594 9.10 0.0029
εcc (%) 1.74 0.1885 30.85 <0.0001
Abbreviations: ACE-I = Angiotension Converting Enzyme Inhibitor, ARB = Angiotension Receptor Block, bpm = beat per minute, εcc = Circumferential Strain,
EF = Ejection Fraction, LVEDV = Left Ventricular Endiastolic Volume, LVM = Left Ventricular Mass.
Table 3 DMD Serial Study Characteristics
Group Group A (Steroids) Group B (Steroids plus) Group A to B
Number of patients n=28 n=31 n=11
Time Interval (mo) Mean=14.9 ± 5.6; range = 8.5-29.7 Mean = 15.1 ± 5.9; range 8.4-35.8 Mean = 15.6 ± 5.9; range = 5.8-25.5
CMR Study Study 1 Study 2 P-value Study 1 Study 2 P-value Study 1 Study 2 P-value
Age (yrs) 9.30 ± 1.5 10.5 ± 1.6 <0.005 11.7 ± 3.4 12.97 ± 3.4 0.148 10.8 ± 2.5 12.0 ± 2.2 0.252
HR (bpm) 101 ± 21 99 ± 16 0.762 105 ± 14 105 ± 15 0.996 100 ± 14 102 ± 18 0.682
LVEDV (mL) 82.7 ± 19.3 86.5 ± 21.6 0.494 84.9 ± 29.2 90.0 ± 30.8 0.499 85.6 ± 18.6 81.2 ± 15.6 0.556
LVM (g) 57.1 ± 15.1 57.7 ± 16.9 0.890 60.9 ± 21.4 65.0 ± 21.4 0.478 61.3 ± 32.2 60.1 ± 14.0 0.909
EF (%) 64.6 ± 6.3 64.4 ± 5.8 0.906 64.9 ± 6.7 62.2 ± 9.1 0.194 61.2 ± 5.0 63.8 ± 5.8 0.261
εcc (%) -14.3 ± 1.6 -13.7 ± 1.5 0.135 -13.4 ± 1.7 -12.1 ± 1.6 0.007 -13.2 ± 1.8 -11.9 ± 2.7 0.179
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